FDA Expands Moderna’s mRNA-1345 RSV Vaccine to Younger Adults
The federal agency approved the company’s mRNA-1345 (mRESVIA) vaccine for people who are between the ages of 18-59.
The federal agency approved the company’s mRNA-1345 (mRESVIA) vaccine for people who are between the ages of 18-59.
The CDC’s new “checklist” comes amid a deadly year of measles outbreaks that is now near record levels.
The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease.
A conversation with Kathryn Edwards, a physician and expert in childhood respiratory diseases and vaccine safety, on RFK Jr.’s latest ACIP shakeup.
BACKGROUND: Despite the significant global impact of the COVID-19 pandemic, limited studies have investigated the long-term cardiovascular sequelae of SARS-CoV-2 infection, particularly among Asian populations.…
In other developments, the ECDC today reported a slow rise in COVID activity in the Europe, which may partly reflect waning population immunity.
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 Dengue survivors are at increased risk for post-infection multi-organ complications, all-cause hospitalization, and death, suggests a study by researchers in…
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 The US Centers for Disease Control and Prevention (CDC) today in its weekly measles update reported 29 more cases, bringing…
The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease.
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 The US Centers for Disease Control and Prevention (CDC) today in its weekly measles update reported 29 more cases, bringing…
After federal health officials made abrupt changes to US Covid-19 vaccine recommendations for pregnant women last month, there’s new confusion and uncertainty about who can…